Schwartz G K, Jiang J, Kelsen D, Albino A P
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, N.Y. 10021.
J Natl Cancer Inst. 1993 Mar 3;85(5):402-7. doi: 10.1093/jnci/85.5.402.
Gastric adenocarcinoma is a common neoplasm worldwide. Patients with completely resected disease often have locoregional recurrence, and adjuvant chemotherapy has failed to reduce the common occurrence of metastases. Protein kinase C (PKC) is thought to be important in tumor cell invasion, but its relationship to gastric cancer cell invasion, and thus metastases, remains unexplored. We recently identified and established invasive and noninvasive human gastric adenocarcinoma cell lines, which can now be used to test agents for inhibition of tumor cell invasion by inhibition of PKC activity.
The objectives were (a) to test threo-dihydrosphingosine (SPC100221), a specific inhibitor of PKC at its regulatory site, and staurosporine, a potent but nonspecific inhibitor of PKC at its catalytic site, for their effects on gastric cancer cell invasion in vitro and (b) to determine whether the expression of PKC isoforms can distinguish invasive from noninvasive gastric cancer cells.
Gastric cancer cell invasion through Matrigel-coated Nuclepore filters in the Boyden chamber assay was analyzed in the presence of graded concentrations of SPC100221 and staurosporine. The invasive SK-GT-1 and SK-GT-5 cell lines and the noninvasive SK-GT-2 and SK-GT-4 cell lines were used. PKC isoform expression was determined by reverse transcription of messenger RNAs to complementary DNA and subsequent amplification by the polymerase chain reaction.
The effects of staurosporine and SPC100221 on tumor cell invasion were tested at drug concentrations that did not inhibit cell proliferation, as evidenced by [3H]thymidine uptake. Staurosporine and SPC100221 at subtoxic doses inhibited human gastric cancer cell invasion by 50% at 5 x 10(-9) M and 2 x 10(-7) M, respectively. The expression of PKC beta was observed in the invasive but not the noninvasive gastric cancer cells. Both types of cells, however, expressed the PKC alpha and PKC gamma isoforms.
Gastric cancer cell invasion can be inhibited by PKC inhibitors, and expression of PKC beta may be a marker of invasiveness in gastric cancer.
PKC appears to represent a new target for inhibition of gastric cancer cell invasion, and SPC100221, in view of its PKC specificity, may provide a model for future drug development in this area. Moreover, PKC beta may have a fundamental role in the development of invasive potential in gastric cancer.
胃腺癌是全球常见的肿瘤。疾病完全切除的患者常出现局部区域复发,辅助化疗未能降低转移的常见发生率。蛋白激酶C(PKC)被认为在肿瘤细胞侵袭中起重要作用,但其与胃癌细胞侵袭以及转移的关系仍未得到探索。我们最近鉴定并建立了侵袭性和非侵袭性人胃腺癌细胞系,现在可用于通过抑制PKC活性来测试抑制肿瘤细胞侵袭的药物。
目标是(a)测试苏式-二氢鞘氨醇(SPC100221)(一种PKC调节位点的特异性抑制剂)和星形孢菌素(一种PKC催化位点的强效但非特异性抑制剂)对体外胃癌细胞侵袭的影响,以及(b)确定PKC同工型的表达是否可区分侵袭性和非侵袭性胃癌细胞。
在存在梯度浓度的SPC100221和星形孢菌素的情况下,通过Boyden室分析法分析胃癌细胞通过Matrigel包被的核孔滤膜的侵袭情况。使用侵袭性SK-GT-1和SK-GT-5细胞系以及非侵袭性SK-GT-2和SK-GT-4细胞系。通过将信使核糖核酸逆转录为互补DNA并随后通过聚合酶链反应进行扩增来确定PKC同工型的表达。
如[3H]胸苷摄取所示,在不抑制细胞增殖的药物浓度下测试了星形孢菌素和SPC100221对肿瘤细胞侵袭的影响。亚毒性剂量的星形孢菌素和SPC100221分别在5×10(-9)M和2×10(-7)M时抑制人胃癌细胞侵袭50%。在侵袭性而非非侵袭性胃癌细胞中观察到PKCβ的表达。然而,两种类型的细胞均表达PKCα和PKCγ同工型。
PKC抑制剂可抑制胃癌细胞侵袭,PKCβ的表达可能是胃癌侵袭性的标志物。
PKC似乎代表了抑制胃癌细胞侵袭的新靶点,鉴于其对PKC的特异性,SPC100221可能为该领域未来的药物开发提供模型。此外,PKCβ可能在胃癌侵袭潜能的发展中起重要作用。